Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study
By: Dražen Huić, Andrea Mutvar, Sandra Kinda-Bašić, Igor Aurer, Martina Ciglar, Darko Grošev, Ivo Radman, Boris Labar and Damir Dodig
Open Access
|Oct 2009References
- Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma.2004; 3: 166-79.
- Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management.2008; 46: 175-98.
- Hoskin PJ. FDG PET in the management of lymphoma: a clinical perspective.2002; 29: 449-51.
- Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.2001; 98: 2930-4.
- Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma.2001; 115: 793-800.
- Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy.2003; 57: 307-15.
- Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?2001; 115: 272-78.
- Nordin AJ, Secondino S, Rahim NA, Pedrazzoli P, Siena S, Rossetti C, et al. Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI.2009; 43: 247-57.
- Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Raja Abdullah RSA. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach.2009; 43: 180-6.
- de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18 FDG - PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.2001; 12: 29-37.
- Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18 F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.2006; 91: 522-9.
- Terasawa T, Nihashi T, Hotta T, Nagai H. 18 F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.2008; 49: 13-21.
- Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first line therapy - is biopsy of FDG - avid lesions still needed?2007; 244: 257-62.
- Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease.2009; 70: 499-506.
- Koga H, Sasaki M, Kuwabara Y, Nakagawa M, Hayashi K, Kaneko K, et al. Lesion detectability of a gamma camera based coincidence system with FDG in patients with malignant tumors: a comparison with dedicated positron emission tomography.2004; 18: 131-6.
- Ak I, Blokland JA, Pauwels EK, Stokkel MP. The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review.2001; 28: 763-78.
- Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin lymphoma and Hodgkin's lymphoma.2004; 31: 22-8.
- Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations.2008; 46: 225-41.
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas.1999; 17: 1244-53.
- Grošev D, Lončarić S, Vandenberghe S, Dodig D. Triple-head gamma camera PET: system overview and performance characteristics.2002; 23: 809-14.
- Grošev D. Performance characteristics of gamma cameras - Reply. [Letter]2003; 24: 440.
- Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.2008; 112: 3989-94.
- Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al.F-FDG PET in malignant lymphoma: significance of positive findings.2005; 32: 749-56.
- Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.2007; 48 Suppl 1:19S-27S.
- Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma.2003; 30: S117-27.
Language: English
Page range: 258 - 263
Published on: Oct 26, 2009
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2009 Dražen Huić, Andrea Mutvar, Sandra Kinda-Bašić, Igor Aurer, Martina Ciglar, Darko Grošev, Ivo Radman, Boris Labar, Damir Dodig, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.